Bill Lundberg, Merus' president and CEO. For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye, as the company talks up its ...

Regeneron's PD-1 inhibitor Libtayo could find wider use for a form of skin cancer known as cutaneous squamous cell carcinoma after showing efficacy in a pivotal trial as adjuvant therapy for patients ...

The engineering advancement has resulted in a unified design for the company's popular automated side loader and front loader ...

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas ASCO Guidelines ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.